MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Repare Therapeutics EPS Ratio 2011-2025 | RPTX
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Repare Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2 | -2.23 | -0.69 | -2.83 | -2.66 | -17.8 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.69 | -17.8 | -4.7 |
Quarterly EPS Ratio Repare Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.08 | -0.39 | -0.71 | - | -0.81 | -0.82 | 0.31 | - | -0.45 | -0.28 | -0.83 | - | 1.8 | -0.91 | -0.83 | - | -0.83 | -0.71 | -0.58 | - | -0.37 | -2.45 | -7.71 | - | -5.03 | -4.16 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.8 | -7.71 | -1.28 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AC Immune SA
ACIU
|
-0.97 | $ 2.8 | 2.19 % | $ 229 M |  Schweiz |
 |
ADiTx Therapeutics
ADTX
|
-3.06 K | $ 2.49 | -11.39 % | $ 32.8 K |  USA |
 |
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M |  Canada |
 |
Abeona Therapeutics
ABEO
|
-2.53 | $ 4.59 | -4.08 % | $ 98.1 M | USA |
 |
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
-0.38 | $ 12.12 | -1.58 % | $ 3.74 B | USA |
 |
Axcella Health
AXLA
|
-1.49 | - | -16.42 % | $ 249 M | USA |
 |
Acer Therapeutics
ACER
|
-1.66 | - | 2.71 % | $ 14 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
-1.91 | $ 5.37 | -20.68 % | $ 194 M | USA |
 |
Atreca
BCEL
|
-2.52 | - | -11.76 % | $ 5.79 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-2.31 | - | -2.5 % | $ 5.88 M | USA |
 |
argenx SE
ARGX
|
-7.99 | $ 919.62 | 2.76 % | $ 25 B |  Niderland |
 |
Ascendis Pharma A/S
ASND
|
-8.28 | $ 203.0 | -3.72 % | $ 5 B |  Danmark |
 |
Achieve Life Sciences
ACHV
|
-1.5 | $ 4.64 | -0.32 % | $ 92 M | USA |
 |
BioDelivery Sciences International
BDSI
|
0.85 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-0.47 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-0.53 | $ 3.36 | 2.73 % | $ 8.08 B |  Australia |
 |
Acasti Pharma
ACST
|
-0.79 | - | 4.01 % | $ 150 M | Canada |
 |
Bellerophon Therapeutics
BLPH
|
-2.08 | - | -74.18 % | $ 955 K | USA |
 |
BioLineRx Ltd.
BLRX
|
-0.12 | $ 3.29 | -1.5 % | $ 908 M |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
2.25 | $ 54.27 | -1.38 % | $ 10.3 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-0.09 | - | -15.15 % | $ 60.3 M |  Britain |
 |
Baudax Bio
BXRX
|
-177 | - | 0.59 % | $ 63 K | USA |
 |
AbbVie
ABBV
|
-0.02 | $ 224.99 | -0.01 % | $ 398 B | USA |
 |
Cara Therapeutics
CARA
|
-2.19 | - | -3.03 % | $ 260 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-0.99 | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
-1.89 | - | - | $ 3.74 B | USA |
 |
BioNTech SE
BNTX
|
42.2 | $ 96.22 | -1.21 % | $ 27.2 B |  Germany |
 |
Codiak BioSciences
CDAK
|
-1.7 | - | -55.98 % | $ 2.15 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-1.08 | $ 18.75 | -0.48 % | $ 2.76 B | USA |
 |
Avid Bioservices
CDMO
|
-2.23 | - | - | $ 789 M | USA |
 |
BioXcel Therapeutics
BTAI
|
-23.5 | $ 1.92 | -7.01 % | $ 4.87 M | USA |
 |
Biogen
BIIB
|
11.2 | $ 179.76 | 1.11 % | $ 26.2 B | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
-2.67 | - | - | $ 7.29 B | USA |
 |
ContraFect Corporation
CFRX
|
-125 | - | -5.16 % | $ 5.39 M | USA |
 |
Beam Therapeutics
BEAM
|
-4.58 | $ 23.52 | -2.22 % | $ 1.94 B | USA |
 |
AbCellera Biologics
ABCL
|
-0.55 | $ 3.45 | -0.72 % | $ 1.02 B | Canada |
 |
Cabaletta Bio
CABA
|
-1.65 | $ 2.37 | -2.67 % | $ 2.77 M | USA |
 |
Clearside Biomedical
CLSD
|
-0.53 | - | - | $ 25.3 M | USA |
 |
Celsion Corporation
CLSN
|
-1.62 | - | -6.63 % | $ 13.9 M | USA |
 |
Clovis Oncology
CLVS
|
-2.29 | - | -7.23 % | $ 13 M | USA |
 |
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-2.84 | - | - | $ 231 M | USA |
 |
Chimerix
CMRX
|
-0.93 | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-2.33 | - | - | $ 401 M | USA |